• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CHRISTOPH MIETHKE GMBH & CO. KG PROGAV SYS W/SA 25 A.CONTROL RESERVOIR; PRO GAV

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CHRISTOPH MIETHKE GMBH & CO. KG PROGAV SYS W/SA 25 A.CONTROL RESERVOIR; PRO GAV Back to Search Results
Model Number FV435T
Device Problems Blocked Connection (2888); Device Operates Differently Than Expected (2913)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 05/12/2018
Event Type  Injury  
Manufacturer Narrative
(b)(4).Manufacturing site evaluation: evaluation on-going.
 
Event Description
Country of complaint: (b)(6).It was reported that 6y po valve is blocked.Explanted.Delivered with the return kit inside an unknown liquid.
 
Manufacturer Narrative
Implant date: unknown month and day in 2012.Investigation: visual inspection a deformation of the outer housing of the progav valve was observed through the visual inspection.Permeability test a permeability test has shown that the progav valve is permeable.Adjustment test the progav valve was tested and is adjustable to all specified pressures.Braking force and brake function test the brake functionality test has shown that the brake function is operational and the braking force is within the given tolerances.Results first, we performed a visual inspection of the progav valve.A deformation of the outer housing of the progav valve was observed through the visual inspection.Next, we tested the permeability, adjustability and opening pressure of the valve, as well as the brake functionality and brake force.The progav valve operates as expected and met all specifications.Finally, we have dismantled the valve.Inside the valve we have found slight build-up of substances (likely protein).Based on our investigation, we are unable to substantiate the claim of occlusion.At the time of our investigation, the progav was shown to be permeable.This is likely due to the deposits observed inside the valves.As described in our literature, the problem encountered is one of the known, inevitable risks of hc-therapy by shunt implants.We can exclude a defect at the time of release.The valve met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PROGAV SYS W/SA 25 A.CONTROL RESERVOIR
Type of Device
PRO GAV
Manufacturer (Section D)
CHRISTOPH MIETHKE GMBH & CO. KG
2 ulanenweg
potsdam, D-144 69
GM  D-14469
MDR Report Key7612029
MDR Text Key111820142
Report Number3004721439-2018-00105
Device Sequence Number1
Product Code JXG
Combination Product (y/n)N
PMA/PMN Number
K103003
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Type of Report Initial,Followup
Report Date 09/24/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received06/18/2018
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date04/30/2017
Device Model NumberFV435T
Device Catalogue NumberFV435T
Device Lot Number4504190366
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer05/23/2018
Distributor Facility Aware Date05/23/2018
Device Age6 YR
Date Manufacturer Received08/10/2018
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Other; Required Intervention;
Patient Age18 YR
Patient Weight60
-
-